Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01270841 · ClinicalTrials.gov registry record · Phase 2
Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism
A Phase 2 study, sponsored by Repros Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
NCT01270841 is a Phase 2 study that has completed, run by Repros Therapeutics. The registered enrollment target is 83 participants.
The verdict
NCT01270841, a Phase 2 study, has completed, sponsored by Repros Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
Study Summary
The Purpose of the study is to determine the effects of Androxal on morning testosterone and reproductive status in men with secondary hypogonadism(confirmed morning Testosterone less than 250 ng/dL), compared to changes with placebo, or Testim (topical testosterone). The effects of Testim versus placebo on reproductive status will also be examined. Study subjects must not be currently using a topical testosterone.
Interventions
- DRUG Placebo
- DRUG topical testosterone
- DRUG Androxal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2011-01 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01270841
The ClinicalTrials.gov registry entry for NCT01270841 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repros Therapeutics, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01270841 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01270841 about?
NCT01270841 is a clinical study titled "Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism". The Purpose of the study is to determine the effects of Androxal on morning testosterone and reproductive status in men with secondary hypogonadism(confirmed morning Testosterone less than 250 ng/dL), compared to changes with placebo, or Testim (topical testosterone). The effects of Testim versus pl...
What is the current status of trial NCT01270841?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2011-01. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01270841?
The interventions under investigation include: Placebo (DRUG), topical testosterone (DRUG), Androxal (DRUG).
Who is sponsoring clinical trial NCT01270841?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.